Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.
An oncology expert shares advances in breast cancer management, with insights on the growing role of CDK4/6 inhibitors, updates to NCCN guidelines, and anticipated research findings at ASCO 2024